Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer

Lung Cancer

Volumn 77, Issue 2, 2012, Pages 252-259

  Male, Heather ^a   Patel, Vijay ^a   Jacob, Mark A ^a   Borrego Diaz, Emma ^a   Wang, Kun ^a   Young, Derek A ^a   Wise, Amanda L ^a   Huang, Chao ^b   Van Veldhuizen, Peter ^a   O'Brien Ladner, Amy ^a   Williamson, Stephen K ^a   Taylor, Sarah A ^a   Tawfik, Ossama ^a   Esfandyari, Tuba ^a   Farassati, Faris ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aurora kinase; CD133; CD44; GGTI; Lung cancer; NSCLC; Ral; RalBP1; Ras; Signaling; Treatment

Indexed keywords

AURORA A KINASE; BINDING PROTEIN; HERMES ANTIGEN; PROTEIN; RAL BINDING PROTEIN 1; RALA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRONCHUS MUCOSA; CANCER CELL; CARCINOGENESIS; CELL DEATH; CELL INVASION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EPITHELIUM CELL; FETUS; GENE SILENCING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD44; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; RAL GTP-BINDING PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863776886     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.03.007     Document Type: Article

References (44)

1. American Cancer Society Cancer Facts & Figures 2010 2010, American Cancer Society, Atlanta, pp. 15-16.
2. Non-small cell lung cancer treatment - National Cancer Institute. 2008. http://www.cancer.gov/CANCERTOPICS/PDQ/TREATMENT/NON-SMALL-CELL-LUNG/PATIENT.
3. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2:e17.
4. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
5. Adjei A.A. K-Ras as a target for lung cancer therapy. J Thorac Oncol 2008, 3:S160-S163.
6. Adjei A.A. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001, 93:1062-1074.
7. Alvarado Y., Giles F.J. Ras as a therapeutic target in hematologic malignancies. Expert Opin Emerg Drugs 2007, 12:271-284.
8. Rowinsky E.K., Windle J.J., Von Hoff D.D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999, 17:3631-3652.
9. Sundaram M.V. RTK/Ras/MAPK signaling. WormBook 2006, 1-19.
10. Singhal S.S., Singhal J., Yadav S., Dwivedi S., Boor P.J., Awasthi Y.C., et al. Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1). Cancer Res 2007, 67:4382-4389.
11. Drake K.J., Singhal J., Yadav S., Nadkar A., Pungaliya C., Singhal S.S., et al. RALBP1/RLIP76 mediates multidrug resistance. Int J Oncol 2007, 30:139-144.
12. Knizhnik A.V., Kovaleva O.B., Laktionov K.K., Mochal'nikova V.V., Komel'kov A.V., Chevkina E.M., et al. Arf6, RalA and BIRC5 protein expression in non small cell lung cancer. Mol Biol (Mosk) 2011, 45:307-315.
13. Bodemann B.O., Ral White M.A. GTPases and cancer: linchpin support of the tumorigenic platform. Nat Rev Cancer 2008, 8:133-140.
14. Camonis J.H., White M.A. Ral GTPases: corrupting the exocyst in cancer cells. Trends Cell Biol 2005, 15:327-332.
15. Yamazaki Y., Kaziro Y., Koide H. Ral promotes anchorage-independent growth of a human fibrosarcoma, HT1080. Biochem Biophys Res Commun 2001, 280:868-873.
16. Chien Y., White M.A. GTPases are linchpin modulators of human tumour-cell proliferation and survival. EMBO Rep 2003, 4:800-806.
17. Bodempudi V., Yamoutpoor F., Pan W., Dudek A.Z., Esfandyari T., Piedra M., et al. Ral overactivation in malignant peripheral nerve sheath tumors. Mol Cell Biol 2009, 29:3964-3974.
18. Smith S.C., Theodorescu D. The Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic target. Urol Oncol 2009, 27:42-47.
19. Yu Y., Feig L.A. Involvement of R-Ras and Ral GTPases in estrogen-independent proliferation of breast cancer cells. Oncogene 2002, 21:7557-7568.
20. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
21. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
22. Breathnach O.S., Freidlin B., Conley B., Green M.R., Johnson D.H., Gandara D.R., et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001, 19:1734-1742.
23. Yamoutpour F., Bodempudi V., Park S.E., Pan W., Mauzy M.J., Kratzke R.A., et al. Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. Mol Cancer Ther 2008, 7:3586-3597.
24. Frankel P., Aronheim A., Kavanagh E., Balda M.S., Matter K., Bunney T.D., et al. RalA interacts with ZONAB in a cell density-dependent manner and regulates its transcriptional activity. EMBO J 2005, 24:54-62.
25. Singh S.K., Gaur R.K. Progress towards therapeutic application of RNA interference for HIV infection. BioDrugs 2009, 23:269-276.
26. Dreyer J.L. Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions. Methods Mol Biol 2010, 614:3-35.
27. Subramanya S., Kim S.S., Manjunath N., Shankar P. RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA. Expert Opin Biol Ther 2010, 10:201-213.
28. von Eije K.J., Berkhout B. RNA-interference-based gene therapy approaches to HIV type-1 treatment: tackling the hurdles from bench to bedside. Antivir Chem Chemother 2009, 19:221-233.
29. Han S.W., Roman J. Targeting apoptotic signaling pathways in human lung cancer. Curr Cancer Drug Targets 2010, 10:566-574.
30. D'Angelo S.P., Pietanza M.C. The molecular pathogenesis of small cell lung cancer. Cancer Biol Ther 2011, 10:1-10.
31. Inamura K., Ishikawa Y. Lung cancer progression and metastasis from the prognostic point of view. Clin Exp Metastasis 2010, 27:389-397.
32. Chiba Y., Sato S., Hanazaki M., Sakai H., Misawa M. Inhibition of geranylgeranyltransferase inhibits bronchial smooth muscle hyperresponsiveness in mice. Am J Physiol Lung Cell Mol Physiol 2009, 297:L984-L991.
33. Chiba Y., Sato S., Misawa M. GGTI-2133, an inhibitor of geranylgeranyltransferase, inhibits infiltration of inflammatory cells into airways in mouse experimental asthma. Int J Immunopathol Pharmacol 2009, 22:929-935.
34. Benten D., Keller G., Quaas A., Schrader J., Gontarewicz A., Balabanov S., et al. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia 2009, 11:934-944.
35. Mortlock A., Keen N.J., Jung F.H., Heron N.M., Foote K.M., Wilkinson R., et al. Progress in the development of selective inhibitors of aurora kinases. Curr Top Med Chem 2005, 5:199-213.
36. Leung E.L., Fiscus R.R., Tung J.W., Tin V.P., Cheng L.C., Sihoe A.D., et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One 2010, 5:e14062.
37. Zhang H.Z., Lin X.G., Hua P., Wang M., Ao X., Xiong L.H., et al. The study of the tumor stem cell properties of CD133+ CD44+ cells in the human lung adenocarcinoma cell line A549. Cell Mol Biol (Noisy-le-grand) 2010, 56(Suppl.):OL1350-OL1358.
38. Shimada Y., Ishii G., Nagai K., Atsumi N., Fujii S., Yamada A., et al. Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci 2009, 100:2054-2059.
39. Tirino V., Camerlingo R., Franco R., Malanga D., La Rocca A., Viglietto G., et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 2009, 36:446-453.
40. Lu Z.Q., Li H.G., Zhang H.Z., Fan M.J., Shen X.M., He X.X. Expression and significance of CD44(+)ESA(+)CD24(-/low), stem cell markers for breast cancer, in non-small-cell lung carcinoma. Ai Zheng 2008, 27:575-579.
41. Pine S.R., Marshall B., Varticovski L. Lung cancer stem cells. Dis Markers 2008, 24:257-266.
42. Hu T., Liu S., Breiter D.R., Wang F., Tang Y., Sun S. Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res 2008, 68:6533-6540.
43. Koch L.K., Zhou H., Ellinger J., Biermann K., Holler T., von Rucker A., et al. Stem cell marker expression in small cell lung carcinoma and developing lung tissue. Hum Pathol 2008, 39:1597-1605.
44. Situ D., Long H., Lin P., Zhu Z., Wang J., Zhang X., et al. Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma. J Cancer Res Clin Oncol 2010, 136:1213-1219.